恒瑞医药创新药获批上市 研发管线持续丰富

Company Project Progress - The company announced that its subsidiary, Suzhou SNDY, received approval from the National Medical Products Administration (NMPA) for its innovative drug, Rilaforpu α injection, on January 8, 2026. This drug is indicated for first-line treatment in patients with PD-L1 positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma in combination with chemotherapy, marking a significant milestone in the company's innovative drug pipeline [1] - The company's innovative drug pipeline continues to expand, with multiple clinical trials at critical stages. As of the 2025 semi-annual report, there are 10 projects in Phase III and 22 projects in Phase II, indicating a need to monitor the application and approval progress of these pipelines in the future [2]